kabutan

Daito Pharmaceutical Co.,Ltd.(4577) Summary

4577
TSE Prime
Daito Pharmaceutical Co.,Ltd.
1,473
JPY
-20
(-1.34%)
Mar 13, 3:30 pm JST
9.24
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
18.6
PBR
0.82
Yield
2.72%
Margin Trading Ratio
57.10
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
1,471 JPY 9.23 USD
Previous Close Mar 12
1,493 JPY 9.39 USD
High Mar 13, 9:00 am
1,484 JPY 9.32 USD
Low Mar 13, 9:19 am
1,465 JPY 9.21 USD
Volume
100,700
Trading Value
0.15B JPY 0.93M USD
VWAP
1473.12 JPY 9.24 USD
Minimum Trading Value
147,300 JPY 924 USD
Market Cap
0.04T JPY 0.28B USD
Number of Trades
369
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Mid
1-Year Average
253
1-Year High Jul 14, 2025
1,532
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 98,700 40,900 0.41
Feb 27, 2026 55,000 40,600 0.74
Feb 20, 2026 51,300 36,200 0.71
Feb 13, 2026 49,200 34,500 0.70
Feb 6, 2026 42,600 33,100 0.78
Company Profile
Daito Pharmaceutical Co., Ltd. specializes in the manufacturing of active pharmaceutical ingredients (APIs) and contract manufacturing of pharmaceutical products, primarily serving generic drug manufacturers.
Sector
Pharmaceuticals
Daito Pharmaceutical Co., Ltd. focuses on the manufacturing and sales of APIs and pharmaceutical products, as well as contract manufacturing and distribution, while also engaging in health food sales. In the API sector, the company manufactures and sells both in-house developed products and those co-developed with partners, maintaining extensive business relationships with domestic and international pharmaceutical companies. The company has a particularly strong track record in supplying APIs, mainly self-developed, to generic drug manufacturers. In pharmaceutical production, Daito actively engages in contract manufacturing of brand-name drugs for major domestic pharmaceutical companies, while also developing and manufacturing generic drugs. With its high-quality control capabilities and production facilities capable of handling various dosage forms, the company is able to undertake manufacturing contracts from major innovative drug companies. Daito's integrated manufacturing system, covering everything from APIs to finished pharmaceutical products, serves as a significant competitive advantage.